Non-canonical NF-κB signalling and ETS1/2 cooperatively drive C250T mutant TERT promoter activation

Nature Cell Biology

Volumn 17, Issue 10, 2015, Pages 1327-1338

  Li, Yinghui ^a   Zhou, Qi Ling ^a,b   Sun, Wenjie ^c   Chandrasekharan, Prashant ^d   Cheng, Hui Shan ^a   Ying, Zhe ^e,f   Lakshmanan, Manikandan ^a   Raju, Anandhkumar ^a   Tenen, Daniel G ^b,g   Cheng, Shi Yuan ^h   Chuang, Kai Hsiang ^d   Li, Jun ^e,f   Prabhakar, Shyam ^c   Li, Mengfeng ^e,f   Tergaonkar, Vinay ^a  

^a INSTITUTE OF MOLECULAR AND CELL BIOLOGY   (Singapore)

^b NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^c GENOME INSTITUTE OF SINGAPORE   (Singapore)

^d AGENCY FOR SCIENCE   (Singapore)

^e SUN YAT SEN UNIVERSITY   (China)

^f SUN YAT SEN UNIVERSITY   (China)

^g HARVARD MEDICAL SCHOOL   (United States)

^h NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GENOMIC DNA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PROTEIN P52; RNA; TELOMERASE; TELOMERASE REVERSE TRANSCRIPTASE; TRANSCRIPTION FACTOR ETS 1; TRANSCRIPTION FACTOR ETS 2; ETS1 PROTEIN, HUMAN; ETS2 PROTEIN, HUMAN; PROTEIN BINDING; TERT PROTEIN, HUMAN; TNFSF12 PROTEIN, HUMAN; TUMOR NECROSIS FACTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASTROCYTOMA; BINDING SITE; CANCER CELL; CANCER GROWTH; CANCER TISSUE; CARCINOGENICITY; CELL PROLIFERATION; CHROMATIN IMMUNOPRECIPITATION; COLONY FORMATION; CONTROLLED STUDY; DNA ISOLATION; ENZYME ACTIVITY; ENZYME REACTIVATION; FEMALE; GEL MOBILITY SHIFT ASSAY; GENE MUTATION; GENETIC TRANSCRIPTION; GLIOBLASTOMA; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MOUSE; MUTANT; NONHUMAN; PLASMID; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN INTERACTION; PROTEIN MOTIF; PROTEIN PURIFICATION; REAL TIME POLYMERASE CHAIN REACTION; RNA EXTRACTION; SIGNAL TRANSDUCTION; SOMATIC MUTATION; TUMOR XENOGRAFT; ANIMAL; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MISSENSE MUTATION; NONOBESE DIABETIC MOUSE; PATHOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA INTERFERENCE; SCID MOUSE; TUMOR CELL LINE; WESTERN BLOTTING; XENOGRAFT;

ANIMALS; BLOTTING, WESTERN; CELL LINE, TUMOR; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GLIOBLASTOMA; HUMANS; MICE, INBRED NOD; MICE, SCID; MUTATION, MISSENSE; NF-KAPPA B; NF-KAPPA B P52 SUBUNIT; PROMOTER REGIONS, GENETIC; PROTEIN BINDING; PROTO-ONCOGENE PROTEIN C-ETS-1; PROTO-ONCOGENE PROTEIN C-ETS-2; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TELOMERASE; TRANSPLANTATION, HETEROLOGOUS; TUMOR NECROSIS FACTORS;

EID: 84942986703     PISSN: 14657392     EISSN: 14764679     Source Type: Journal    
DOI: 10.1038/ncb3240     Document Type: Article

References (68)

1. Harley, C. B., Futcher, A. B. & Greider, C. W. Telomeres shorten during ageing of human fibroblasts. Nature 345, 458-460 (1990).
2. Cong, Y.-S., Wright, W. E. & Shay, J. W. Human telomerase and its regulation. Microbiol. Mol. Biol. Rev. 66, 407-425 (2002).
3. Stewart, S. A. & Weinberg, R. A. Telomeres: cancer to human aging. Annu. Rev. Cell Dev. Biol. 22, 531-557 (2006).
4. Verdun, R. E. & Karlseder, J. Replication and protection of telomeres. Nature 447, 924-931 (2007).
5. Günes, C. & Rudolph, K. L. The role of telomeres in stem cells and cancer. Cell 152, 390-393 (2013).
6. Counter, C. M. The roles of telomeres and telomerase in cell life span. Mutat. Res. 366, 45-63 (1996).
7. Hanahan, D. & Weinberg, R. A. Hallmarks of cancer: the next generation. Cell 144, 646-674 (2011).
8. Low, K. C. & Tergaonkar, V. Telomerase: central regulator of all of the hallmarks of cancer. Trends Biochem. Sci. 38, 426-434 (2013).
9. Ghosh, A. et al. Telomerase directly regulates NF-B-dependent transcription. Nat. Cell Biol. 14, 1270-1281 (2012).
10. Martinez, P. & Blasco, M. A. Telomeric and extra-Telomeric roles for telomerase and the telomere-binding proteins. Nat. Rev. Cancer 11, 161-176 (2011).
11. Koh, C. M. et al. Telomerase regulates MYC-driven oncogenesis independent of its reverse transcriptase activity. J. Clin. Invest. 125, 2109-2122 (2015).
12. Li, Y. & Tergaonkar, V. Noncanonical functions of telomerase: implications in telomerase-Targeted cancer therapies. Cancer Res. 74, 1639-1644 (2014).
13. Horn, S. et al. TERT promoter mutations in familial and sporadic melanoma. Science 339, 959-961 (2013).
14. Huang, F. W. et al. Highly recurrent TERT promoter mutations in human melanoma. Science 339, 957-959 (2013).
15. Greider, C. W. Wnt regulates TERT-putting the horse before the cart. Science 336, 1519-1520 (2012).
16. Hoffmeyer, K. et al. Wnt/-catenin signaling regulates telomerase in stem cells and cancer cells. Science 336, 1549-1554 (2012).
17. Shin, E. M. et al. DEAD-box helicase DP103 defines metastatic potential of human breast cancers. J. Clin. Invest. 124, 3807-3824 (2014).
18. Tong, L. & Tergaonkar, V. Rho protein GTPases and their interactions with NF-B: crossroads of inflammation and matrix biology. Biosci. Rep. 34, 283-295 (2014).
19. Yin, L., Hubbard, A. K. & Giardina, C. NF-B regulates transcription of the mouse telomerase catalytic subunit. J. Biol. Chem. 275, 36671-36675 (2000).
20. Yang, W. et al. EGFR-induced and PKC' monoubiquitylation-dependent NF-B activation upregulates PKM2 expression and promotes turmorigenesis. Mol. Cell 48, 771-784 (2012).
21. Sampl, S. et al. Expression of telomeres in astrocytoma WHO grade 2 to 4: TERRA level correlates with telomere length, telomerase activity, and advanced clinical grade. Transl. Oncol. 5, 56-65 (2012).
22. Brennan, C. W. et al. The somatic genomic landscape of glioblastoma. Cell 155, 462-477 (2013).
23. Heidenreich, B. et al. Telomerase reverse transcriptase promoter mutations in primary cutaneous melanoma. Nat. Commun. 5, 3401 (2014).
24. Killela, P. J. et al. TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal. Proc. Natl Acad. Sci. USA 110, 6021-6026 (2013).
25. Babayeva, N. D. et al. Structural basis of Ets1 cooperative binding to palindromic sequences on stromelysin-1 promoter DNA. Cell Cycle 9, 3126-3134 (2010).
26. Newman, J. A., Cooper, C. D. O., Aitkenhead, H. & Gileadi, O. Structural insights into the auto-regulation and cooperativity of the human transcription factor Ets-2. J. Biol. Chem. 290, 8539-8549 (2015).
27. Oeckinghaus, A., Hayden, M. S. & Ghosh, S. Crosstalk in NF-B signaling pathways. Nat. Immunol. 12, 695-708 (2011).
28. Akincilar, S. C. et al. Quantitative assessment of telomerase components in cancer cell lines. FEBS Lett. 589, 974-984 (2015).
29. Yi, X., Shay, J. W. & Wright, W. E. Quantitation of telomerase components and hTERT mRNA splicing patterns in immortal human cells. Nucleic Acids Res. 29, 4818-4825 (2001).
30. Roos, C. et al. Soluble and transmembrane TNF-like weak inducer of apoptosis differentially activate the classical and noncanonical NF-B pathway. J. Immunol. 185, 1593-1605 (2010).
31. Salzmann, S. et al. Fibroblast growth factor inducible (Fn14)-specific antibodies concomitantly display signaling pathway-specific agonistic and antagonistic activity. J. Biol. Chem. 288, 13455-13466 (2013).
32. Heusch, M., Lin, L., Geleziunas, R. & Greene, W. C. The generation of nfkb2 p52: mechanism and efficiency. Oncogene 18, 6201-6208 (1999).
33. Ghosh, S. & Karin, M. Missing pieces in the NF-B puzzle. Cell 109, S81-S96 (2002).
34. Sun, S.-C. Non-canonical NF-B signaling pathway. Cell Res. 21, 71-85 (2011).
35. Razani, B., Reichardt, A. D. & Cheng, G. Non-canonical NF-B signaling activation and regulation: principles and perspectives. Immunol. Rev. 244, 44-54 (2011).
36. Siggers, T. et al. Principles of dimer-specific gene regulation revealed by a comprehensive characterization of NF-B family DNA binding. Nat. Immunol. 13, 95-102 (2012).
37. Zhao, B. et al. The NF-B genomic landscape in lymphoblastoid B cells. Cell Rep. 8, 1595-1606 (2014).
38. Sun, W. et al. TherMos: estimating protein-DNA binding energies from in vivo binding profiles. Nucleic Acids Res. 41, 5555-5568 (2013).
39. Kumar, V. et al. Uniform, optimal signal processing of mapped deep-sequencing data. Nat. Biotechnol. 31, 615-622 (2013).
40. Li, H. et al. The sequence alignment/map format and SAMtools. Bioinformatics 25, 2078-2079 (2009).
41. Joseph, R. et al. Integrative model of genomic factors for determining binding site selection by estrogen receptor-. Mol. Syst. Biol. 6, 456 (2010).
42. Bonizzi, G. et al. Activation of IKK-Target genes depends on recognition of specific-B binding sites by RelB:p52 dimers. EMBO J. 23, 4202-4210 (2004).
43. Fusco, A. J. et al. Stabilization of RelB requires multidomain interactions with p100/p52. J. Biol. Chem. 283, 12324-12332 (2008).
44. Ramakrishnan, P., Wang, W. & Wallach, D. Receptor-specific signaling for both the alternative and the canonical NF-B activation pathways by NF-B-inducing kinase. Immunity 21, 477-489 (2004).
45. Ishii, N. et al. Frequent co-Alterations of TP53, p16/CDKN2A, p14ARF, PTEN tumor suppressor genes in human glioma cell lines. Brain Pathol. 9, 469-479 (1999).
46. Bassuk, A. G., Anandappa, R. T. & Leiden, J. M. Physical interactions between Ets and NF-B/NFAT proteins play an important role in their cooperative activation of the human immunodeficiency virus enhancer in T cells. J. Virol. 71, 3563-3573 (1997).
47. Longoni, N. et al. ETS transcription factor ESE1/ELF3 orchestrates a positive feedback loop that constitutively activates NF-B and drives prostate cancer progression. Cancer Res. 73, 4533-4547 (2013).
48. Kar, A. & Gutierrez-Hartmann, A. Molecular mechanisms of ETS transcription factormediated tumorigenesis. Crit. Rev. Biochem. Mol. Biol. 48, 522-543 (2013).
49. Jankowski, A., Prabhakar, S. & Tiuryn, J. TACO: a general-purpose tool for predicting cell-Type-specific transcription factor dimers. BMC Genomics 15, 208 (2014).
50. Bell, R. J. et al. Cancer. The transcription factor GABP selectively binds and activates the mutant TERT promoter in cancer. Science 348, 1036-1039 (2015).
51. Yilmaz, Z. B., Weih, D. S., Sivakumar, V. & Weih, F. RelB is required for Peyer's patch development: differential regulation of p52-RelB by lymphotoxin and TNF. EMBO J. 22, 121-130 (2003).
52. Franzoso, G. et al. Requirement for NF-B in osteoclast and B-cell development. Genes Dev. 11, 3482-3496 (1997).
53. Hofmann, J., Mair, F., Greter, M., Schmidt-Supprian, M. & Becher, B. NIK signaling in dendritic cells but not in T cells is required for the development of effector T cells and cell-mediated immune responses. J. Exp. Med. 208, 1917-1929 (2011).
54. Lind, E. F. et al. Dendritic cells require the NF-B2 pathway for cross-presentation of soluble antigens. J. Immunol. 181, 354-363 (2008).
55. Thu, Y. M. et al. NF-B inducing kinase (NIK) modulates melanoma tumorigenesis by regulating expression of pro-survival factors through the-catenin pathway. Oncogene 31, 2580-2592 (2012).
56. Zhang, W. et al. A NIK-IKK-module expands ErbB2-induced tumor-initiating cells by stimulating nuclear export of p27/Kip1. Cancer Cell 23, 647-659 (2013).
57. Keats, J. J. et al. Promiscuous mutations activate the noncanonical NF-B pathway in multiple myeloma. Cancer Cell 12, 131-144 (2007).
58. Baldwin, A. S. Regulation of cell death and autophagy by IKK and NF-B: critical mechanisms in immune function and cancer. Immunol. Rev. 246, 327-345 (2012).
59. Perkins, N. D. The diverse and complex roles of NF-B subunits in cancer. Nat. Rev. Cancer 12, 121-132 (2012).
60. Dey, A. et al. Hexamethylene bisacetamide (HMBA) simultaneously targets AKT and MAPK pathway and represses NF-B activity: implications for cancer therapy. Cell Cycle 7, 3759-3767 (2008).
61. Tergaonkar, V., Pando, M., Vafa, O., Wahl, G. & Verma, I. p53 stabilization is decreased upon NF-B activation: a role for NF-B in acquisition of resistance to chemotherapy. Cancer Cell 1, 493-503 (2002).
62. Saccani, S., Marazzi, I., Beg, A. A. & Natoli, G. Degradation of promoter-bound p65/RelA is essential for the prompt termination of the nuclear factor-B response. J. Exp. Med. 200, 107-113 (2004).
63. Lee, D. W. et al. The NF-B RelB protein is an oncogenic driver of mesenchymal glioma. PLoS ONE 8, e57489 (2013).
64. Cherry, E., Lee, D., Jung, J.-U. & Sitcheran, R. Tumor necrosis factor-like weak inducer of apoptosis (TWEAK) promotes glioma cell invasion through induction of NF-B-inducing kinase (NIK) and noncanonical NF-B signaling. Mol. Cancer 14, 9 (2015).
65. Mashiko, D. et al. Generation of mutant mice by pronuclear injection of circular plasmid expressing Cas9 and single guided RNA. Sci. Rep. 3 (2013).
66. ENCODE An integrated encyclopedia of DNA elements in the human genome. Nature 489, 57-74 (2012).
67. Kim, N. W. & Wu, F. Advances in quantification and characterization of telomerase activity by the telomeric repeat amplification protocol (TRAP). Nucleic Acids Res. 25, 2595-2597 (1997).
68. Ran, F. A. et al. Genome engineering using the CRISPR-Cas9 system. Nat. Protoc. 8, 2281-2308 (2013).